HLB 토토 바카라 signs exclusive supply agreement with Bioserve in India, launching full-scale 토토 바카라tide raw material exports

[by Lee, Young Sung] HLB PEP, a company specializing in peptide-based technologies, announced on August 5 the signing of an exclusive peptide material supply agreement with the Indian biotechnology firm Bioserve Biotechnologies. This agreement is expected to facilitate the global expansion of HLB PEP’s material exports.

Under the terms of the agreement, Bioserve will import high-quality peptide raw materials produced by HLB PEP and serve as the exclusive distributor for research use across India. HLB PEP emphasized the significance of this partnership, noting that it represents a meaningful step in expanding the global reach of HLB PEP’s peptide production technology, the only company in Korea to have obtained GMP certification.

Bioserve, a subsidiary of the Japanese regenerative medicine firm Reprocell, is widely recognized in India for its technological expertise, particularly in the fields of DNA synthesis and genetic analysis services. Its client base includes major Indian universities, public research institutes, and biotechnology companies.

Since its incorporation into the HLB Group in March, HLB PEP has actively pursued international market expansion. In May of this year, the company’s enuresis treatment raw material, ‘desmopressin,’ received approval as a finished pharmaceutical product. Furthermore, HLB PEP is expected to undergo a U.S. FDA inspection next year in preparation for the launch of its infertility treatment raw material, ‘Ganirelix,’ in the U.S. market.

"This agreement with Bioserve represents a strategic step toward expanding our sales in the highly promising Indian market,” said Shim Kyoung-jae, CEO of HLB PEP. “We expect strong synergy in the Indian biotechnology sector through collaboration with Bioserve, which possesses an extensive market network."

On the other hand, the Indian 토토 바카라tide therapeutics market is projected to reach USD 985 million (KRW 1.36 trillion) by 2023 and is expected to grow at a compound annual growth rate (CAGR) of 12.6%, reaching an estimated USD 2.26 billion by 2030.